Evidence for distinct DNA- and RNA-based mechanisms of 5-fluoracil cytotoxicity in Saccharomyces cerevisiae

Yeast

Volumn 24, Issue 10, 2007, Pages 861-870

  Hoskins, Jason ^a   Butler, J Scott ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

5 fluoracil; Exosome; RNA; RNA processing; Rrp6

Indexed keywords

FLUOROURACIL; FOLIC ACID ANTAGONIST; FUNGAL DNA; FUNGAL RNA; THYMIDINE PHOSPHATE; URACIL; URIDINE PHOSPHATE;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA METABOLISM; DNA REPAIR; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; EXCISION REPAIR; FUNGUS GROWTH; GENETIC ANALYSIS; GROWTH RATE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RNA METABOLISM; RNA PROCESSING; SACCHAROMYCES CEREVISIAE; STRAIN DIFFERENCE; WILD TYPE;

ANTIMETABOLITES, ANTINEOPLASTIC; DNA; DNA REPAIR; FLUOROURACIL; RNA; SACCHAROMYCES CEREVISIAE; URACIL; URIDINE MONOPHOSPHATE;

SACCHAROMYCES CEREVISIAE;

EID: 35348999495     PISSN: 0749503X     EISSN: 10970061     Source Type: Journal    
DOI: 10.1002/yea.1516     Document Type: Article

References (53)

1. Andrulis ED, Werner J, Nazarian A, et al. 2002. The RNA processing exosome is linked to elongating RNA polymerase II in Drosophila. Nature 420: 837-841.
2. Bisson LF, Thorner J. 1982. Mutations in the pho80 gene confer permeability to 5′-mononucleotides in Saccharomyces cerevisiae. Genetics 102: 341-359.
3. Boiteux S, Guillet M. 2004. Abasic sites in DNA: repair and biological consequences in Saccharomyces cerevisiae. DNA Repair (Amst) 3: 1-12.
4. Bunz F, Hwang PM, Torrance C, et al. 1999. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263-269.
5. Burke DJ, Church D. 1991. Protein synthesis requirements for nuclear division, cytokinesis, and cell separation in Saccharomyces cerevisiae. Mol Cell Biol 11: 3691-3698.
6. Butler JS. 2002. The yin and yang of the exosome. Trends Cell Biol 12: 90-96.
7. Carrico CK, Glazer RI. 1979. Augmentation by thymidine of the incorporation and distribution of 5-fluorouracil in ribosomal RNA. Biochem Biophys Res Commun 87: 664-670.
8. Dolnick BJ, Pink JJ. 1983. 5-Fluorouracil modulation of dihydrofolate reductase RNA levels in methotrexate-resistant KB cells. J Biol Chem 258: 13299-13306.
9. Doong SL, Dolnick BJ. 1988. 5-Fluorouracil substitution alters pre-mRNA splicing in vitro. J Biol Chem 263: 4467-4473.
10. Dornfeld K, Johnson M. 2005. AP endonuclease deficiency results in extreme sensitivity to thymidine deprivation. Nucleic Acids Res 33: 6644-6653.
11. Engelbrecht C, Ljungquist I, Lewan L, Yngner T. 1984. Modulation of 5-fluorouracil metabolism by thymidine. In vivo and in vitro studies on RNA-directed effects in rat liver and hepatoma. Biochem Pharmacol 33: 745-750.
12. Fang F, Hoskins J, Butler JS. 2004. 5-Fluorouracil enhances exosome-dependent accumulation of polyadenylated rRNAs. Mol Cell Biol 24: 10766-10776.
13. Fang F, Phillips S, Butler JS. 2005. Rat1p and Rai1p function with the nuclear exosome in the processing and degradation of rRNA precursors. RNA 11: 1571-1578.
14. Foury F. 1997. Human genetic diseases: a cross-talk between man and yeast. Gene 195: 1-10.
15. Giaever G, Shoemaker DD, Jones TW, et al. 1999. Genomic profiling of drug sensitivities via induced haplo-insufficiency. Nat Genet 21: 278-283.
16. Giaever G, Flaherty P, Kumm J, et al. 2004. Chemogenomic profiling identifying the functional interactions of small molecules in yeast. Proc. Natl. Acad. Sci. USA 101: 793-798.
17. Glazer RI, Hartman KD. 1983. In vitro translation of messenger RNA following exposure of human colon carcinoma cells in culture to 5-fluorouracil and 5-fluorouridine. Mol Pharmacol 23: 540-546.
18. Greenhalgh DA, Parish JH. 1989. Effects of 5-fluorouracil on cytotoxicity and RNA metabolism in human colonic carcinoma cells. Cancer Chemother Pharmacol 25: 37-44.
19. Greenhalgh DA, Parish JH. 1990. Effect of 5-fluorouracil combination therapy on RNA processing in human colonic carcinoma cells. Br J Cancer 61: 415-419.
20. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. 1997. Integrating genetic approaches into the discovery of anticancer drugs. Science 278: 1064-1068.
21. Heitman J, Movva NR, Hall MN. 1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253: 905-909.
22. Hieronymus H, Yu MC, Silver PA. 2004. Genome-wide mRNA surveillance is coupled to mRNA export. Genes Dev 18: 2652-2662.
23. Houseley J, LaCava J, Tollervey D. 2006. RNA-quality control by the exosome. Nat Rev Mol Cell Biol 7: 529-539.
24. Houseley J, Tollervey D. 2006. Yeast Trf5p is a nuclear poly(A) polymerase. EMBO Rep 7: 205-211.
25. Kadaba S, Krueger A, Trice T, et al. 2004. Nuclear surveillance and degradation of hypomodified initiator tRNAMet in S. cerevisiae. Genes Dev 18: 1227-1240.
26. Kouzminova EA, Kuzminov A. 2006. Fragmentation of replicating chromosomes triggered by uracil in DNA. J Mol Biol 355: 20-33.
27. Kuai L, Fang F, Butler JS, Sherman F. 2004. Polyadenylation of rRNA in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 101: 8581-8586.
28. LaCava J, Houseley J, Saveanu C, et al. 2005. RNA degradation by the exosome is promoted by a nuclear polyadenylation complex. Cell 121: 713-724.
29. Ladner RD. 2001. The role of dUTPase and uracil-DNA repair in cancer chemotherapy. Curr Protein Pept Sci 2: 361-370.
30. Lee SK, Yu SL, Prakash L, Prakash S. 2002. Yeast RAD26, a homolog of the human CSB gene, functions independently of nucleotide excision repair and base excision repair in promoting transcription through damaged bases. Mol Cell Biol 22: 4383-4389.
31. Lenz HJ, Manno DJ, Danenberg KD, Danenberg PV. 1994. Incorporation of 5-fluorouracil into U2 and U6 snRNA inhibits mRNA precursor splicing. J Biol Chem 269: 31962-31968.
32. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 10: 934-947.
33. Longley DB, Harkin DP, Johnston PG. 2003. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338.
34. Lum PY, Armour CD, Stepaniants SB, et al. 2004. Discovering modes of action for therapeutic compounds using a genomewide screen of yeast heterozygotes. Cell 116: 121-137.
35. Mercure S, Cousineau L, Montplaisir S, Belhumeur P, Lemay G. 1997. Expression of a reporter gene interrupted by the Candida albicans group I intron is inhibited by base analogs. Nucleic Acids Res 25: 431-437.
36. Mercure S, Montplaisir S, Lemay G. 1993. Correlation between the presence of a self-splicing intron in the 25S rDNA of C. albicans and Strains susceptibility to 5-fluorocytosine. Nucleic Acids Res 21: 6020-6027.
37. Parker WB, Cheng YC. 1990. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48: 381-395.
38. Patton JR. 1993. Multiple pseudouridine synthase activities for small nuclear RNAs. Biochem J 290(2): 595-600.
39. Pritchard DM, Watson AJ, Potten CS, Jackman AL, Hickman JA. 1997. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci USA 94: 1795-1799.
40. Randerath K, Agrawal HP, Randerath E. 1983. tRNA alterations in cancer. Recent Results Cancer Res 84: 103-120.
41. Samuelsson T. 1991. Interactions of transfer RNA pseudouridine synthases with RNAs substituted with fluorouracil. Nucleic Acids Res 19: 6139-6144.
42. Santi DV, Hardy LW. 1987. Catalytic mechanism and inhibition of tRNA (uracil-5-)methyltransferase: evidence for covalent catalysis. Biochemistry 26: 8599-8606.
43. Schreiber SL, Crabtree GR. 1992. The mechanism of action of cyclosporin A and FK506. Immunol Today 13: 136-142.
44. Seiple L, Jaruga P, Dizdaroglu M, Stivers JT. 2006. Linking uracil base excision repair and 5-fluorouracil toxicity in yeast. Nucleic Acids Res 34: 140-151.
45. Sherman F. 1991. Getting started with yeast. Methods Enzymol 194: 3-21.
46. Steinmetz LM, Scharfe C, Deutschbauer AM, et al. 2002. Systematic screen for human disease genes in yeast. Nat Genet 31: 400-404.
47. Tinkelenberg BA, Hansbury MJ, Ladner RD. 2002. dUTPase and uracil-DNA glycosylase are central modulators of antifolate toxicity in Saccharomyces cerevisiae. Cancer Res 62: 4909-4915.
48. 1/S transition state enzyme, in p53-mutated cells. Biochem Pharmacol 55: 1353-1360.
49. Waldorf AR, Polak A. 1983. Mechanisms of action of 5-fluorocytosine. Antimicrob Agents Chemother 23: 79-85.
50. Winzeler EA, Shoemaker DD, Astromoff A, et al. 1999. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285: 901-906.
51. Wyers F, Rougemaille M, Badis G, et al. 2005. Cryptic pol II transcripts are degraded by a nuclear quality control pathway involving a new poly(A) polymerase. Cell 121: 725-737.
52. Zhao X, Yu YT. 2004. Pseudouridines in and near the branch site recognition region of U2 snRNA are required for snRNP biogenesis and pre-mRNA splicing in Xenopus oocytes. RNA 10: 681-690.
53. Zhao X, Yu YT. 2007. Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo. Nucleic Acids Res 35: 550-558.